Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.60 |
| ▸ | FNTB | P49356 | 6/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14511191 | 0.89 | MAPT (0.46) | FNTAFNTBTAAR1ALDH1A1HTR6 | |
| SCHEMBL1751240 | 0.85 | FNTA (0.64) | FNTAFNTBTAAR1PGGT1BSLC1A3 | |
| SCHEMBL7163224 | 0.81 | FNTA (0.58) | FNTAFNTBTAAR1PGGT1BALDH1A1 | |
| SCHEMBL27687483 | 0.79 | MAPT (0.50) | FNTAFNTBALDH1A1MEN1KMT2A | |
| SCHEMBL13624242 | 0.79 | FNTA (0.70) | FNTAFNTBTAAR1PGGT1BSLC1A3 | |
| SCHEMBL1752171 | 0.76 | ALDH1A1 (0.64) | TAAR1ALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL8112651 | 0.75 | FNTA (1.00) | FNTAFNTBPGGT1B | |
| SCHEMBL9274495 | 0.73 | FFAR1 (0.48) | ALDH1A1FFAR1MEN1KMT2A | |
| SCHEMBL13884895 | 0.73 | MAPT (0.42) | FNTAFNTBTAAR1ALDH1A1CYP2D6 | |
| SCHEMBL16189140 | 0.73 | AOC3 (0.44) | FNTAFNTBTAAR1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968748-B2 | Process for resolving racemic mixtures and a diastereoisomeric complex of a resolving agent and an enantiomer of interest | ABIOGEN PHARMA S.P.A. (IT) | 2011-06-28 | — | — | US | claimed |
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2009-11-26 | — | — | US | claimed |
| US-7968748-B2 | Process for resolving racemic mixtures and a diastereoisomeric complex of a resolving agent and an enantiomer of interest | ABIOGEN PHARMA S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| US-7968748-B2 | Process for resolving racemic mixtures and a diastereoisomeric complex of a resolving agent and an enantiomer of interest | ABIOGEN PHARMA S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2009-11-26 | — | — | US | disclosed |
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2009-11-26 | — | — | US | disclosed |
| EP-1986996-A2 | A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | Abiogen Pharma S.p.A. (IT) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007088571-A2 | A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | SRR, EPHX2, ALOX5 | FNTA 150/4885FNTB 672/4885TAAR1 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.